Novartis AG (NVS) (Q2FY23)
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz.
The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products.
The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics.
Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol.
The strong Q2 growth of the company can be attributed to the excellent performance of four key products: Entresto®, Kesimpta®, Pluvicto®, and Kisqali®. These products have significantly contributed to the company’s success. Entresto®, has achieved robust double-digit growth across all geographical regions. Cosentyx®, has shown signs of sales stabilization and is expected to grow in 2HFY23.
Novartis’s stock price showed a volatile trend in past 3-months. It increased by 2.22% during the period. The stock price increased by 20.7% in past 1-year. The stock has a 52-week high of $105.61 and its 52-week low is $74.09.
In the past 3 years, the stock has given returns of 24.46%. NVS has a 50-day moving Avg. and 200-day moving Avg. of $100.06 and $91.61, respectively.
This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.
– Enterprise Value
– CrispIdea Forecast
– CrispIdea Segment Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum
Actual & Historical Performance
– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Developments
– M&A Deals
– Price Performance
Stock Price Performance
No of Pages: 37
To download the previous quarter’s equity report CLICK HERE
To Download other equity/ stock reports CLICK HERE
Follow our LinkedIn page for more updates.